What are the marketed Biguanide drugs?

Marketed Biguanide drugs include hypoglycemic Agents(metformin), metformin 0.85 twice daily for 6 months, Metformin hydrochoride, Mandated back ground therapy, or Metformin HCl alone, Placebo plus metformin.

Biguanide

18 marketed 17 in Phase 3

This page covers all Biguanide drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting AMP-activated protein kinase (AMPK); complex I of the mitochondrial electron transport chain, AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase, AMP-activated protein kinase (AMPK), mitochondrial glycerophosphate dehydrogenase.

Targets

Marketed (18)

hypoglycemic Agents(metformin) · First Affiliated Hospital of Wenzhou Medical University · Endocrinology / Diabetes
Metformin reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues, thereby lowering blood glucose levels in type 2 diabetes.
metformin 0.85 twice daily for 6 months · Xiang Guang-da · Diabetes
Metformin reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues, lowering blood glucose levels in type 2 diabetes.
Metformin hydrochoride · University of Massachusetts, Worcester · Diabetes
Metformin reduces hepatic glucose production and improves insulin sensitivity, thereby lowering blood glucose levels in type 2 diabetes.
Mandated back ground therapy · Sanofi · Diabetes
Metformin works by decreasing glucose production in the liver, increasing insulin sensitivity, and enhancing glucose uptake in muscles.
or Metformin HCl alone · Bristol-Myers Squibb · Diabetes
Metformin HCl reduces hepatic glucose production and improves insulin sensitivity, thereby lowering blood glucose levels in patients with type 2 diabetes.
Placebo plus metformin · University Magna Graecia · Diabetes
Metformin reduces hepatic glucose production and improves insulin sensitivity, while the placebo control arm receives no active pharmacological intervention.
Metformin Large Pack · GlaxoSmithKline · Diabetes
Metformin reduces hepatic glucose production and improves insulin sensitivity, thereby lowering blood glucose levels in type 2 diabetes.
Metformin cloridrate · University Magna Graecia · Diabetes
Metformin hydrochloride reduces hepatic glucose production and improves insulin sensitivity, thereby lowering blood glucose levels in patients with type 2 diabetes.
Placebo-Metformin · Steno Diabetes Center Copenhagen · Diabetes
Metformin reduces hepatic glucose production and improves insulin sensitivity, thereby lowering blood glucose levels in type 2 diabetes.
Metformin discontinue · University of Texas Southwestern Medical Center · Diabetes
This entry represents a discontinuation of metformin therapy rather than a new drug entity.
Metformin up-titration · Research Clinical Centre of the Russian Railways, JSC · Diabetes
Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK).
Metformin continue · University of Texas Southwestern Medical Center · Endocrinology/Diabetes
Metformin reduces hepatic glucose production and improves insulin sensitivity, thereby lowering blood glucose levels in type 2 diabetes.
Metformin Small Pack · GlaxoSmithKline · Diabetes
Metformin reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues, lowering blood glucose levels in type 2 diabetes.
Met IR · Elcelyx Therapeutics, Inc. · Endocrinology / Diabetes
Met IR is a formulation of metformin immediate-release that reduces hepatic glucose production and improves insulin sensitivity to lower blood glucose levels in type 2 diabetes.
Metformin / Placebo treatment for 4 months · Norwegian University of Science and Technology · Diabetes
Metformin reduces hepatic glucose production and improves insulin sensitivity, thereby lowering blood glucose levels in patients with type 2 diabetes.
Metformin IR · AstraZeneca · Diabetes
Metformin reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues, lowering blood glucose levels in type 2 diabetes.
MET · Ente Ospedaliero Ospedali Galliera · Endocrinology / Diabetes
MET is a metformin-based antidiabetic agent that reduces hepatic glucose production and improves insulin sensitivity.
Metformin only · Sheba Medical Center · Diabetes
Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK) and inhibiting mitochondrial complex I.

Phase 3 pipeline (17)

Marketed Control · Procter and Gamble · Diabetes
Metformin works by decreasing glucose production in the liver and increasing insulin sensitivity.
Metformin (Background drug) · Sanofi · Diabetes
Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK).
Biguanides (BG) · Eli Lilly and Company · Diabetes
Biguanides reduce hepatic glucose production and improve insulin sensitivity by activating AMP-activated protein kinase (AMPK) and inhibiting mitochondrial glycerol-3-phosphate dehydrogenase.
Metformin (open-label) · Medical College of Wisconsin · Diabetes
Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK) and inhibiting mitochondrial complex I.
Biguanide (BG) · Eli Lilly and Company · Diabetes
Biguanides reduce hepatic glucose production and improve insulin sensitivity by activating AMP-activated protein kinase (AMPK) and inhibiting mitochondrial complex I.
Metformin - Rescue · Merck Sharp & Dohme LLC · Diabetes
Metformin reduces hepatic glucose production and improves insulin sensitivity to lower blood glucose levels in type 2 diabetes.
Placebo plus metformin IR · AstraZeneca · Diabetes
Metformin reduces hepatic glucose production and improves insulin sensitivity, while placebo serves as a control comparator in this combination study.
Open-label Metformin · Merck Sharp & Dohme LLC · Diabetes
Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK).
Metformin 1500mg, QD · Daewoong Pharmaceutical Co. LTD. · Diabetes
Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK) and inhibiting mitochondrial complex I.
Metformin alone · Mount Sinai Hospital, Canada · Diabetes
Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK).
Metformin HCI XR · The University of Texas Health Science Center at San Antonio · Diabetes
Metformin HCl XR reduces hepatic glucose production and improves insulin sensitivity to lower blood glucose levels in type 2 diabetes.
Continuous metformin · Mount Sinai Hospital, Canada · Diabetes
Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK) and inhibiting mitochondrial complex I.
Comparator: placebo metformin · Merck Sharp & Dohme LLC · Diabetes
Metformin reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues.
Standard therapy for INCS · Eli Lilly and Company · Diabetes
Metformin works by decreasing glucose production in the liver, increasing insulin sensitivity, and enhancing glucose uptake in muscles.
Metformin (Active Rescue) · AstraZeneca · Diabetes
Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK).
Metformin (blinded) · AstraZeneca · Diabetes
Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK).
Metformin immediate release · Janssen Research & Development, LLC · Diabetes
Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK) and inhibiting mitochondrial complex I.